Navigation Links
FDA OKs Drug That Targets Rare Form of Cystic Fibrosis
Date:1/31/2012

TUESDAY, Jan. 31 (HealthDay News) -- Kalydeco, the first drug that targets the defective protein behind a rare form of the deadly lung disorder cystic fibrosis, was approved Tuesday by the U.S. Food and Drug Administration.

One patient advocate group applauded the decision.

"Today marks an important milestone in our journey to find a cure for cystic fibrosis," Robert Beall, president and CEO of the Cystic Fibrosis Foundation, said in a news release. "Kalydeco addresses the underlying cause of cystic fibrosis, and the science behind the drug has opened exciting new doors to research and development that may eventually lead to additional therapies that will benefit more people."

People with cystic fibrosis have mutations in a gene that produces a protein called CFTR, which regulates the movement of ions (such as chloride) and water in the body. This defect causes sticky mucus to accumulate in the lungs and other organs, resulting in infections, digestive problems and usually death in early adulthood.

Cystic fibrosis affects an estimated 30,000 people in the United States and is the most common fatal genetic disease in the white population. About 1,200 (4 percent) of cystic fibrosis patients have a rare form of the disease caused by a specific G551D mutation in the cystic fibrosis transmembrane regulator (CFTR) gene, the FDA explained in a news release.

The twice-a-day pill Kalydeco (ivacaftor) was approved for patients with this rare form of cystic fibrosis. The pill, which is taken with fat-containing food, helps the protein made by the CFTR gene function better, the FDA explained.

Two 48-week clinical trials involving 213 patients -- one with patients ages 12 and older and the other with patients ages 6 to 11 -- showed that the drug improved lung function and reduced other symptoms of cystic fibrosis.

The most common side effects of the drug were upper respiratory tract infection, headache, stoma
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
2. Hot Pepper Itch Remedy Targets Kidney Disease Patients Suffering From Chronic Pruritus
3. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
4. Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building
5. FDA Targets Safety Problems With Infusion Drug Pumps
6. Global Summit on International Breast Health Targets Breast Health Improvements in Developing Countries, June 9-11, 2010, in Chicago
7. Combination therapy targets stubborn leukemia stem cells
8. Miami meeting on radiation therapy targets patient safety
9. Researcher targets gene regulators on link between arsenic, cancer
10. MSU targets womens health research with $2.5 million grant
11. TGen finds therapeutic targets for rare cancer in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... SpaRoom® is pleased to ... and premier diffuser, is now available in sleek black, ... motor for maximum quality. The new black ultrasonic spa ... SpaRoom.com for $60 along with the traditional pearl white ... create a long-lasting, tranquil mist. Add a few drops ...
(Date:7/23/2014)... July 23, 2014 Relias Learning, the ... health and human services markets, continued to expand its ... record growth in its core markets and further expansion ... the use of SaaS-based training solutions accelerate across a ... Relias Learning. “Health and human services organizations, in particular, ...
(Date:7/23/2014)... 23, 2014 Throughout the month of July, ... plenty of new items. Also, it is hosting a couple ... its collection of short summer beach wedding dresses for ... popular styles in it. Additionally, these outfits are now offered ... , “As one of the world’s leading suppliers, LunaDress is ...
(Date:7/23/2014)... Canada (PRWEB) July 23, 2014 Princeview ... clinics, is announcing the importance of having a complete ... by a dentist to ensure oral health care, as ... examination,” says Dr. Janice Mummery, founder of Princeview Dental. ... is not able to see. Just by observing the ...
(Date:7/23/2014)... Denver, CO (PRWEB) July 23, 2014 Daily ... released a cheaper and safer alternative to Botox called ... Facial Serum is an anti-aging product used to help people ... Technology Facial Serum can be used as a safe alternative ... does not have any toxins or health risks as opposed ...
Breaking Medicine News(10 mins):Health News:SpaRoom® Unveils New Sleek Color, Improved AromaMist™ 2Health News:Relias Learning announces Q2 results - continues record growth and new market expansion 2Health News:LunaDress Continues To Enrich Product Line By Offering Short Summer Beach Wedding Dresses 2Health News:Princeview Dental, One of Etobicoke’s Trusted Dental Clinics, Addresses the Need to Have Complete Oral Exams 2Health News:Local Denver Skin Care Company Releases Safer Alternative to Botox 2
... recommended that infant be put to sleep in separate beds ... The number of infant deaths as a consequence of parents ... considerably increased over the recent years according to a report, ... weight infants, male infants and those that sleep on their ...
... melanoma among the Hispanic population of California. In a new ... a peer-reviewed journal of the American Cancer Society, the researchers ... is of the thicker variety, meaning that it has relatively ... is by far a minor percentage of all skin cancers, ...
... baby from Pakistan was given a new lease of life ... Sri M.G. Ramachandra Medical College and Hospital.// Fifteen-month-old Maxwell Qayyum ... was operated upon in Chennai, and he is reported to ... team of pediatricians conducted the surgery. ,The ...
... with pulmonary embolism can be identified through risk factors like blood ... of death due to this factor // can be treated ... Medicine. The condition is due to an abrupt blockage of an ... dislodged. In the US, this is a major health hazard. This ...
... his team from Johns Hopkins University School of Medicine ... of Medicine // that Antiretroviral combination drug of Tenofovir, ... controlling HIV load compared to most widely used drug ... trial called ‘study 934’ was conducted in 517 HIV ...
... maternity care is expected, with a London- based NHS hospital ... pregnant women who pay ?4,000. The novel scheme would be ... ,The provision of such a cost-effective one-to-one service during ... impossible to reach due to high demand. However, it continues ...
Cached Medicine News:Health News:Invasive Skin Cancer On The Rise in Hispanics 2Health News:London Hospital Provides Specialized Care For Pregnant Women 2
(Date:7/23/2014)... , July 23 2014 Ampio Pharmaceuticals, Inc. ... new headquarters, manufacturing and research facility: Ampio ... 80112 Direct: (720) 437-6500 Michael ... pharmaceutical drug manufacturing facility will be fully operational this ... first batches of Ampion TM necessary to accommodate ...
(Date:7/23/2014)... , July 23, 2014  ArmaGen, a ... therapies to treat severe neurological disorders, announced today ... and collaboration agreement with Shire plc to develop ... potential treatment of both the central nervous system ... Also known as MPS II, Hunter syndrome is ...
(Date:7/22/2014)... July 23, 2014   - Investment ... Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a fully-fledged oncology pharmaceutical ... be investing US$30 million in Remiges BioPharma Fund (hereinafter ... Taiho has a long history of developing ... and cancer patients. Our development of TAS-102 is an ...
Breaking Medicine Technology:Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 2ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome 3Taiho Pharmaceutical Invests US$30 Million in Remiges BioPharma Fund, LP 2
... September 9, 2011 The Board of the ... today it agreed to ratify the proposal of the US ... package, designed with the help of EFCG and US industry ... User Fees Act (GDUFA). GDUFA requires the FDA ...
... Advanced Wound Management division of Smith & Nephew (LSE: SN; ... studies on a range of products and therapies from their ... RENASYS* wound care portfolio. The data demonstrate advanced healing strategies ... products. Results of the studies are being presented at the ...
Cached Medicine Technology:European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 2Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 3Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: